Targeted treatment of bronchogenic carcinoma

Česká verzia

Authors: M. Černovská
Authors place of work: Přednostka: prof. MUDr. Martina Vašáková, PhD ; 1. lékařská fakulta a Thomayerova nemocnice ; Pneumologická klinika 1. LF UK a TN ; Univerzita Karlova v Praze
Published in the journal: Prakt. Lék. 2020; 100(1): 3-7
Category: Reviews

Summary

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Targeted cancer therapies are sometimes called "molecularly targeted therapies". Targeted drugs work differently from standard chemotherapy. It is a type of treatment that uses drugs to attack cancer cells with EGFR or ALK gene changes (EGFR and ALK inhibitors) or block new blood tumour vessel growth (angiogenesis inhibitors). At present, target therapy is part of the routine management for patients with nonsmall cell lung cancer (NSCLC), especially in advanced stages

Keywords:

Angiogenesis – mutations – targeted therapy – EGFR – ALK

Zdroje

1. Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 2019; 137: 113–122.

2. Planchard D, Popat S, Kerr K, et al. Metastatic Non-Small-Cell Lung Cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv192–iv237.

3. Horn L, Mansfield A, Szczęsna A. First-Line Atezolizumab plus chemotherapy in extensive-stage Small-Cell Lung Cancer. N Engl J Med 2018; 379: 2220–2229.

4. Skřičková J, Kolek V, a kol. Základy moderní pneumoonkologie II. Praha: Maxdorf 2017.

5. Ryška A, Petruželka L, Skřičková J, a kol. Interdisciplinární konsenzus pro prediktivní vyšetřování u nemalobuněčného karcinomu plic (NSCLC). Studia pneumologica et phthiseologica 2012; 72(3): 168.

6. Lee CK, Wu YL, Ding PN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutation and clinical charakteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer. J Clin Oncol 2015; 33(17): 1958–1965.

7. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4(9): 1046–1061.

8. Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013; 5(216): 216ra177.

9. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15(11): 1236–1244.

10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550.

11. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11(4): 689–708.

12. Gandhi S, Chen H, Zhao Y, Dy GK. First-line treatment of advanced ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl) 2015; 6: 71–82.

13. Amin A, Ersek J, Kim ES, O’Day S. Immunooncology. Bevacizumab mechanism of action [online]. Dostupné z: https://www.healio.com/hematology-oncology/learn-immuno-oncology/clinical-indications/colorectal-cancer [cit. 2019-11-19]